**Supplementary Table S1.** Reported cases of exogenous *Exophiala* endophthalmitis.

| Authors | Country | Patient Gender (Age) | Predisposing Factors | Symptoms and Signs | Diagnosis Methods | Pathogen | Treatment | Antifungal susceptibility | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Hammer et al. [13] | USA | Male (31) | Post-traumatic fungal endophthalmitis following penetrating eye injury | NR | Fungal culture (vitreous aspirate) | *Exophiala jeanselmei* | Intravitreal and intravenous AMB, oral 5-FC | NR | Fungal eradication achieved, but vision loss due to total retinal detachment |
| Margo & Fitzgerald [19] | USA | Female (75) | Cataract surgery, prolonged steroid use | Decreased vision, painful eye | Vitrectomy; fungal culture | *Wangiella* (*Exophiala*) *dermatitidis* | Multiple vitrectomies, intravitreal AMB (5 μg) | NR | Eye enucleated due to pain |
| Hofling-Lima et al. [14] | Brazil | Female (67) | Corticosteroid treatment | Corneal abscess, severe anterior chamber reaction | Anterior chamber culture | *Exophiala jeanselmei* | Intravitreal AMB (multiple doses), systemic AMB | NR | Ocular atrophy after recurrence |
| Hofling-Lima et al. [14] | Brazil | Female (52) | Controlled diabetes | Severe iridocyclitis, diffuse uveitis with hypopyon | Anterior chamber and vitreous culture | *Exophiala jeanselmei* | Vitrectomy, systemic and intraocular AMB | NR | Ocular atrophy after recurrence |
| Benaoudia et al. [17] | France | Male (31) | Penetrating keratoplasty, prolonged steroid use | Ocular pain, corneal infiltrate; anterior chamber involvement | Fungal culture; histopathology | *Wangiella* (*Exophiala*) *dermatitidis* | Systemic and intraocular AMB; surgical intervention (keratoplasty) | Susceptible to AMB, NYS, KET, resistant to 5-FC, MIC not reported | Poor visual outcome (persistent graft edema) |
| Huber et al. [15] | USA | Female | Cataract surgery | Decreased vision, pain | Vitreous cultures | *Exophiala werneckii* | Vitrectomy, intravitreal AMB, systemic antifungals | NR | Resolution of infection, improvement in visual acuity |
| Clamp et al. [5] | USA | Male (60) | Crohn's disease, herpes zoster | Persistent intraocular inflammation, | Vitrectomy; vitreous culture, PCR | *Exophiala dermatitidis* | Multiple vitrectomies, intravitreal AMB | NR | Eye enucleated after recurrence |

https://doi.org/10.3390/jof12050368

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | keratitis, prior keratoplasty | dense vitritis, retinal infiltrates | | | (2.5µg; 5µg), intravenous AMB | | |
| Quintero-Estades et al. [21] | Puerto Rico | Female (65) | Cataract surgery | Pain, reduced vision, corneal melt | Anterior segment surgery; fungal culture | *Exophiala* spp. | Penetrating keratoplasty, intravitreal VOR (50 µg), topical VOR (1%) | NR | Improved to 20/80, later required regrafting |
| Homa et al. [8] | India | Male (59) | Post-cataract surgery | Persistent anterior chamber inflammation, fluffy growth on posterior capsule | Vitrectomy; posterior capsule culture, molecular identification | *Exophiala dermatitidis* | Vitrectomy, removal of IOL and capsular bag, intravitreal VOR (100 µg), oral FLU | **MIC values:** AMB (0.33 µg/mL); CLO (0.33 µg/mL), ECO (0.83 µg/mL), FLU (2.67 µg/mL), ITR (0.25 µg/mL), KET (0.25 µg/mL), POS (0.38 µg/mL), VOR (0.25 µg/mL), NAT (8 µg/mL), ECH (>32 µg/mL) | Visual acuity improved to 6/9 |
| Kim et al. [18] | South Korea | Female (70) | Diabetes, cataract surgery | Vision impairment, anterior chamber inflammation, vitreous opacity, hypopyon | Biopsy, fungal culture | *Exophiala* spp. | Vitrectomy, removal of IOL; VOR eye drops (topical, 5%) | NR | Visual acuity improved to 1.0, no recurrence after 6 months |
| Van der Merwe et al. [16] | South Africa | Female (75) | Diabetes, cataract surgery | Pain, photophobia, corneal infiltrate | Vitreous aspirate, fungal culture, DNA sequencing | *Exophiala oligosperma* | Vitrectomy, intravitreal AMB (5 µg), topical AMB (0.15%), oral VOR (200 mg twice daily) | **MIC values:** VOR (0.5 µg/mL); ITR (0.25 µg/mL); AMB (0.25 µg/mL); CAS | Eye enucleated after deterioration |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | (0.25 μg/mL); NAT (0.25 μg/mL). | |
| Shah et al. [20] | India | Male (64) | Diabetes, complicated cataract surgery | Pain, redness, reduced vision | Biopsy; fungal culture; lactophenol blue staining | *Exophiala dermatitidis* | Vitrectomy, intravitreal VOR (100 μg); oral FLU (150 mg twice daily) | NR | Visual acuity improved to 6/9 |
| Present case | Serbia | Female (80) | Diabetes, cataract surgery with intraocular lens implantation, prolonged steroid use | Pain, redness, progressive vision loss, corneal infiltrate, hypopyon | Conjunctival swab; corneal scraping; anterior chamber fluid | *Exophiala dermatitidis* | Systemic VOR; repeated anterior chamber irrigation with VOR | **MIC values:** AMB (0.25 μg/mL); FLU (4 μg/mL); ITR (0.06 μg/mL); VOR (0.03 μg/mL); POS (0.03 μg/mL); 5-FC (4 μg/mL); ECH (>8 μg/mL). | Eye enucleated after deterioration |

**Table legend:** NR, not reported; IOL, intraocular lens; MIC, minimum inhibitory concentration; AMB, Amphotericin B; NYS, nystatin; CLO, clotrimazole; ECO, econazole; FLU, fluconazole; ITR, itraconazole; KET, ketoconazole; POS, posaconazole; VOR, voriconazole; NAT, natamycin; 5-FC, 5-fluorocytosine; CAS, caspofungin ECH, echinocandins (caspofungin, anidulafungin, micafungin)